Daclizumab

Generic Name: Daclizumab

Brand Names: -

Drug Type: -

Chemical Formula: -

CAS Number: -

Unique Ingredient Identifier: -

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Study to Evaluate the Amount of Medications That May be Removed From the Body During Plasmapheresis

Withdrawn

Conditions: Kidney Transplantation
Plasmapheresis

First Posted Date: 2005-09-20

Last Posted Date: 2016-10-21

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Registration Number: NCT00203281

Locations: 🇺🇸
Columbia University, New York, New York, United States
🇺🇸
Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States

Study Evaluating Sirolimus in Kidney Transplant Recipients

Phase 3

Completed

Conditions: Graft vs Host Disease
Kidney Transplantation

Interventions: Drug: sirolimus
Drug: cyclosporine
Drug: mycophenolate mofetil
Drug: corticosteroids
Drug: daclizumab

First Posted Date: 2005-09-19

Last Posted Date: 2010-04-28

Lead Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer

Target Recruit Count: 61

Registration Number: NCT00195273

Steroid-Free Versus Steroid-Based Immunosuppression in Pediatric Renal (Kidney) Transplantation

Phase 1

Completed

Conditions: Kidney Transplant
Renal Transplantation
Kidney Transplantation
Kidney Diseases
Renal Transplant

Interventions: Drug: Daclizumab
Drug: Mycophenolate mofetil (MMF)
Drug: Prednisone
Drug: Ganciclovir
Drug: Tacrolimus
Drug: Valganciclovir
Drug: Trimethoprim and sulfamethoxazole

First Posted Date: 2005-09-01

Last Posted Date: 2016-11-29

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 130

Registration Number: NCT00141037

Locations: 🇺🇸
UCLA - Department of Pediatrics, Division of Nephrology, Los Angeles, California, United States
🇺🇸
Children's Hospital Boston - Division of Nephrology, Boston, Massachusetts, United States
🇺🇸
Children's Hospital of New Orleans-Department of Pediatric Nephrology, New Orleans, Louisiana, United States

and more 9 locations

Human Anti-Tac (Daclizumab) to Treat Juvenile Idiopathic Arthritis (JIA)-Associated Uveitis

Phase 2

Completed

Conditions: Anterior Uveitis
Arthritis, Juvenile Idiopathic
Iritis
Immunosuppression

Interventions: Drug: Daclizumab

First Posted Date: 2005-08-15

Last Posted Date: 2017-01-30

Lead Sponsor: National Eye Institute (NEI)

Target Recruit Count: 6

Registration Number: NCT00130637

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Daclizumab to Treat HIV-Infected Patients

Phase 1

Completed

Conditions: HIV Infections

First Posted Date: 2004-03-31

Last Posted Date: 2017-07-02

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 10

Registration Number: NCT00080431

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Daclizumab and Sirolimus to Treat Uveitis

Phase 1

Completed

Conditions: Uveitis

First Posted Date: 2004-03-05

Last Posted Date: 2017-07-02

Lead Sponsor: National Eye Institute (NEI)

Target Recruit Count: 6

Registration Number: NCT00078689

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Humanized Anti-IL-2 Receptor Monoclonal Antibody in Moderate-to-severe Ulcerative Colitis

Phase 2

Completed

Conditions: Ulcerative Colitis
Gastrointestinal Disease
Inflammatory Bowel Disease

First Posted Date: 2003-11-18

Last Posted Date: 2009-07-20

Lead Sponsor: Facet Biotech

Target Recruit Count: 150

Registration Number: NCT00073047

Locations: 🇺🇸
St. Louis Center for Clinical Research, St. Louis, Missouri, United States
🇺🇸
The University of Chicago Hospital, Chicago, Illinois, United States
🇺🇸
Long Island Clinical Research Associates, Great Neck, New York, United States

and more 31 locations

A Randomized Trial of Recombinant Humanized Anti-IL-2 Receptor Antibody (Daclizumab) Versus Antithymocyte Globulin (ATG) to Treat the Cytopenia of Myelodysplastic Syndrome (MDS)

Phase 2

Completed

Conditions: Myelodysplastic Syndromes

First Posted Date: 2003-11-13

Last Posted Date: 2008-03-04

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 132

Registration Number: NCT00072969

Locations: 🇺🇸
National Heart, Lung and Blood Institute (NHLBI), Bethesda, Maryland, United States

Zenapax (Daclizumab) to Treat Relapsing Remitting Multiple Sclerosis

Phase 2

Completed

Conditions: Multiple Sclerosis, Relapsing-Remitting

First Posted Date: 2003-11-03

Last Posted Date: 2017-07-02

Lead Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)

Target Recruit Count: 16

Registration Number: NCT00071838

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Daclizumab to Treat Non-Infectious Sight-Threatening Uveitis

Phase 2

Completed

Conditions: Uveitis

First Posted Date: 2003-10-08

Last Posted Date: 2017-07-02

Lead Sponsor: National Eye Institute (NEI)

Target Recruit Count: 6

Registration Number: NCT00070759

Locations: 🇺🇸
National Eye Institute (NEI), Bethesda, Maryland, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy